1. RECENT TRENDS IN VIVO RADIOPHARMACEUTICAL DEVELOPMENTS

Abstract

Knowledge acquired in medical study fields is utilized for the development of diagnostic, therapeutic and preventive methods in medicine. Nuclear Medicine, having a history over a quarter a century, is a unique procedure in medicine and is yet a new technology in diagnoses. Recent annual meetings of the Society of Nuclear Medicine (U.S.A) show us many promising radiopharmaceuticals. Out of them, ^<99m>Tc HMPAO, ^<99m>Tc isonitriles, ^<99m>Tc BATOs, ^<123>I-faty acid derivatives ^<123>I-MIBG and radioisotope labeled monoclonal antibodies seem advanced. Each ^<99m>Tc labeled compound has been selected purposively with constant efforts from many similar compounds. ^<99m>Tc-labeled compounds have now a new developmental procedure of their membrane passing pharmacokinetics. The developmental procedures of the other radiolabeled ligands depend almost on pharmacokinetics of ligands, and characters of those ligands will may have relations directly or indirectly with substances in blood to be tested by in-vitro diagnostic methods like a radioimmunoassay.